Shrinks In Sneakers

Tag: medication

  • Navigating First-Episode Psychosis: A Delicate Balance

    Navigating First-Episode Psychosis: A Delicate Balance

    In my practice, I encounter many cases of first-episode psychosis, a critical period that requires thoughtful and precise intervention. The decisions made during this time can set a patient on the path to long-term recovery or, unfortunately, towards a lifetime of challenges.

    There are a few guiding principles I always adhere to:

    1. Most antipsychotics can be effective, but it’s important to choose carefully.
    2. Lower doses often suffice to achieve remission in first-episode psychosis. Starting with a medication that has a lower risk of cardiometabolic side effects and weight gain is crucial, especially for young patients. They shouldn’t be burdened with long-term physical side effects as they navigate their recovery.

    Predicting whether a patient will experience a single episode or develop a chronic condition like schizophrenia is challenging. While family history and substance use, particularly cannabis, can provide clues, there is still uncertainty.

    I believe that after 6-12 months of treatment, it’s worth considering tapering the antipsychotic to the lowest effective dose, with a careful eye on any signs of relapse. Unfortunately, what I often see is that both patients and clinicians overlook the subtle signs of relapse because they’ve mutually decided to discontinue the medication. By the time I see them again, the situation has worsened.

    Early psychosis treatment requires a delicate balance between managing symptoms and minimizing long-term side effects, all while keeping a close watch for signs of relapse. Careful planning is key to setting patients on the best path forward.

  • FDA Greenlights Breakthrough Schizophrenia Medication: Here’s How It Works

    FDA Greenlights Breakthrough Schizophrenia Medication: Here’s How It Works

    The FDA approved Cobenfy

    Schizophrenia is a complex and debilitating mental disorder characterized by a range of symptoms, including hallucinations, delusions, cognitive deficits, and emotional dysregulation. Despite advancements in antipsychotic medications, many patients experience incomplete symptom relief and significant side effects. As a result, there is a growing interest in alternative therapeutic targets, including the muscarinic acetylcholine receptors (mAChRs).

    Muscarinic Acetylcholine Receptors (mAChRs)

    The mAChRs are G protein-coupled receptors involved in various central nervous system functions, including cognition, learning, memory, and mood regulation. There are five subtypes of mAChRs (M1-M5), with the M1, M2, M3, and M4 subtypes playing significant roles in modulating neural activity related to schizophrenia.

    M1 Muscarinic Agonists

    The M1 receptor is primarily expressed in the cortex and hippocampus, regions crucial for cognitive processing. M1 agonists have shown promise in improving cognitive deficits and reducing psychotic symptoms in schizophrenia. Research indicates that M1 activation can enhance cholinergic neurotransmission and modulate glutamate and dopamine systems, potentially alleviating both positive and negative symptoms.

    M2 Muscarinic Agonists

    M2 receptors are predominantly found in the basal forebrain and play a role in modulating acetylcholine release. Although less studied than M1, M2 agonists may help balance neurotransmitter release, contributing to improved cognitive function and reduced psychotic symptoms.

    M3 Muscarinic Agonists

    The role of M3 receptors in schizophrenia is not as well understood as M1 and M4 receptors. However, M3 receptors are involved in various physiological processes, including insulin secretion and smooth muscle contraction. Research is ongoing to determine their potential therapeutic benefits in schizophrenia.

    M4 Muscarinic Agonists

    M4 receptors are highly expressed in the striatum, a brain region implicated in the regulation of motor control and reward processing. M4 agonists have shown potential in reducing dopaminergic hyperactivity, which is associated with positive symptoms of schizophrenia, such as hallucinations and delusions. Additionally, M4 activation may help mitigate side effects associated with conventional antipsychotics, such as extrapyramidal symptoms.

    Clinical Implications and Future Directions

    The therapeutic potential of M1-M4 muscarinic agonists in schizophrenia is an exciting area of research. Targeting these receptors may offer a novel approach to address the cognitive and negative symptoms of schizophrenia, which are often resistant to current treatments. Ongoing clinical trials and preclinical studies are crucial to understanding the efficacy, safety, and mechanisms of action of these compounds.

    Conclusion The exploration of M1-M4 muscarinic agonists represents a promising frontier in the treatment of schizophrenia. By modulating cholinergic, glutamatergic, and dopaminergic systems, these agents have the potential to provide more comprehensive symptom relief with fewer side effects compared to traditional antipsychotics. Continued research and development are essential to bring these innovative treatments to clinical practice, offering hope for improved outcomes for individuals with schizophrenia.

  • Semaglutide: The Diabetes Drug with a Life-Saving Twist Against Opioid Overdose

    Semaglutide: The Diabetes Drug with a Life-Saving Twist Against Opioid Overdose

    A recent study published in JAMA Network Open investigated the relationship between semaglutide, a medication commonly used for type 2 diabetes (T2D), and the risk of opioid overdose in patients with both T2D and opioid use disorder (OUD). The researchers analyzed the health records of over 33,000 individuals, finding that those taking semaglutide had a significantly lower risk of opioid overdose compared to those using other diabetes medications. Semaglutide reduced overdose risk by as much as 58% when compared to insulin, and by 54% compared to metformin.

    The findings suggest that semaglutide may have protective effects in people with OUD and T2D, although more research is needed to confirm the mechanisms behind these effects and to validate the results through clinical trials. Researchers emphasized that these promising outcomes highlight the potential therapeutic value of semaglutide beyond diabetes management, though the study faced limitations due to its observational design and the possibility of uncontrolled variables.

    Further research is required to understand how semaglutide could be integrated into treatment strategies for opioid use disorder​

    Link to the article: https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2824054?utm_source=silverchair&utm_medium=email&utm_campaign=article_alert-jamanetworkopen&utm_content=wklyforyou&utm_term=092524&adv=null

  • Psilocybin Outshines Escitalopram: A Breakthrough in Depression Treatment

    Psilocybin Outshines Escitalopram: A Breakthrough in Depression Treatment

    The article Effect of psilocybin versus escitalopram on depression symptom severity in patients with moderate-to-severe major depressive disorder: observational 6-month follow-up of a phase 2, double-blind, randomised, controlled trialreports findings from an extended observation period on the comparative effects of psilocybin and escitalopram in treating depression. Here are the key points:

    Study Design: This was a 6-month follow-up of a Phase 2, double-blind, randomized controlled trial. It compared the effects of psilocybin (a psychedelic compound) and escitalopram (a common SSRI) on depression symptoms in patients with moderate-to-severe major depressive disorder (MDD).

    Participants: Patients with moderate-to-severe MDD were randomly assigned to either psilocybin or escitalopram groups. Both treatments were administered in a controlled clinical setting

    Primary Outcome: Depression symptom severity was measured using the QIDS-SR-16 (Quick Inventory of Depressive Symptomatology–Self-Report) scale at various time points, including baseline, during the treatment phase, and at the 6-month follow-up.

    Results:

    Both groups showed improvement in depression symptoms, but the psilocybin group had a greater reduction in symptoms compared to the escitalopram group.

    The effects of psilocybin were found to be more rapid and sustained over the 6-month period.

    Remission and Response Rates: A higher proportion of patients in the psilocybin group achieved remission and clinically significant response compared to those in the escitalopram group.

    Safety and Side Effects: Both treatments were generally well-tolerated. However, psilocybin was associated with transient, mild-to-moderate side effects, mostly during the acute phase of treatment (e.g., perceptual disturbances).

    Conclusion: Psilocybin demonstrated more pronounced and longer-lasting antidepressant effects compared to escitalopram at the 6-month follow-up. This suggests that psilocybin could be a viable alternative treatment for moderate-to-severe depression, but further research is necessary to confirm long-term safety and efficacy.

  • Be Cautious with Gabapentin in Patients on MAT for Opioid Use Disorder 

    Be Cautious with Gabapentin in Patients on MAT for Opioid Use Disorder 

    In my practice, I frequently see patients on Medication-Assisted Treatment (MAT) for opioid use disorder, whether it’s Suboxone or methadone, also being prescribed high-dose gabapentin—often without a clear indication for its use. This raises some serious red flags. ⚠️

    While gabapentin can be useful in certain situations, we know there’s an increased risk of overdose when it’s combined with opioids, especially in those with a history of opioid use disorder. Gabapentin can suppress the central nervous system, making it more dangerous in combination with other sedating medications.

    If there’s no solid reason for the prescription, it’s best to steer clear. Always prioritize safety and question if gabapentin is truly necessary in these cases. Let’s keep patient care and harm reduction at the forefront.

    💡 Key takeaway: If there’s no clear indication, think twice before prescribing gabapentin to someone on MAT. Their safety depends on it.

  • The Journey to Becoming the Best Version of Yourself

    The Journey to Becoming the Best Version of Yourself

    I’ve never shared this story before, but lately, I’ve been reflecting on what it truly means to grow, to fight your inner battles, and become the best version of yourself. From the beginning, I knew that before I could serve others, I had to conquer my own demons — embark on my very own hero’s journey.

    For those unfamiliar with the old way of landing a residency before the pandemic, let me tell you—it was intense. As a fourth-year med student, you would travel across the country, conducting interviews in person. The nerves of sitting in a room with a program director, explaining why you were the right fit, were real. But there’s something irreplaceable about sitting face-to-face with someone, feeling their energy, picking up on their vibe. It told you whether or not you could actually work with that person. That is something lost in today’s tele-interviews, and honestly, it’s a lesson that extends beyond medical school—it’s about life and human connection.

    I vividly remember interviewing at a program where my final interview was with the director. We sat in silence for a minute as she looked over my CV. She didn’t introduce herself, didn’t ask how I was, just silence. Then, she saw the hobbies section where I had written that I enjoyed self-improvement seminars and books. Her reaction? She immediately began grilling me.

    “You like reading self-help books?” she asked, and I could feel the judgment. I told her I prefer to call it ‘education,’ but in her eyes, I had already failed. She looked at me as if someone on a journey to improve themselves didn’t belong there. She ended the interview right then, essentially telling me I wasn’t cut out for her program.

    At the time, I was hurt—angry, even. I felt like I had been dismissed for being human, for not being perfect. But that interaction has aged well. Today, I don’t look back with the same anger; instead, I see it as a powerful lesson.

    Here’s the thing: the expectation that we should be “perfect” is a lie. We are all works in progress. None of us have it all figured out, despite what social media shows. And that’s okay—it’s something to embrace, not run from.So to anyone out there, especially future psychiatrists, remember this: your own journey matters. The process of growth never ends, and it’s the imperfections that make us human—and that’s where real strength lies.

  • Trapped in My Own Mind: This Anxiety is Killing Me

    Trapped in My Own Mind: This Anxiety is Killing Me

    Anxiety is a very real and powerful force that can take a toll on both your mind and body. In today’s fast-paced world, it’s easy to feel trapped in an anxiety prison, with stressors constantly surrounding us. The weight of it all can be overwhelming, leaving you exhausted mentally and physically. Remember, you’re not alone in this struggle. Take moments for self-care, reach out for support, and know that breaking free from anxiety’s grip is possible. Small steps can lead to big changes.

  • Want to Live Longer with a Serious Mental Health Condition? Say No to Alcohol, Drugs, and Smoking!

    Want to Live Longer with a Serious Mental Health Condition? Say No to Alcohol, Drugs, and Smoking!

    The article “Major Psychiatric Disorders, Substance Use Behaviors, and Longevity” explores the complex relationships between psychiatric disorders, substance use, and life expectancy. The authors examine how conditions like schizophrenia, bipolar disorder, and major depression affect longevity, often leading to reduced lifespans. This is largely due to increased risk factors, such as poor physical health, unhealthy lifestyles, and increased rates of suicide.

    Substance use behaviors, including alcohol, tobacco, and drug use, often co-occur with psychiatric disorders, compounding the negative effects on longevity. The article emphasizes the need for better integration of mental health and substance use treatment into healthcare systems. It also advocates for targeted interventions to reduce mortality rates, improve the quality of life, and enhance access to comprehensive care for individuals with psychiatric disorders.

    Link to the article: https://jamanetwork.com/journals/jamapsychiatry/fullarticle/2820199

  • When Anxiety Turns to Anger: A Hidden Struggle

    When Anxiety Turns to Anger: A Hidden Struggle

    Anxiety manifests in many ways, and one of the most dangerous is when it turns into anger. Imagine living on edge all day—from the moment you wake up until you finally get home. The constant tension builds as you’re stuck in traffic, stressed at work, and juggling a million thoughts. By the time you walk in the door, your emotional reserves are empty. A simple spilled drink can set you off, leading to an outburst your partner doesn’t understand. It seems small, but the anxiety has been simmering all day, and that moment was its breaking point.

    How can we prevent ourselves from reaching this boiling point?

    Here are some practical tips to stop anxiety in its tracks:

    Grounding Techniques

    • 5-4-3-2-1 Exercise: Focus on 5 things you can see, 4 you can touch, 3 you can hear, 2 you can smell, and 1 you can taste. Bring your mind back to the present moment.
    • Use Your Senses: Engage with something textured, calming sounds, or soothing scents like lavender.

     Deep Breathing

    • Box Breathing: Inhale for 4 seconds, hold for 4, exhale for 4, pause for 4. Repeat until you feel more grounded.
    • Diaphragmatic Breathing: Breathe deeply into your diaphragm to activate relaxation.

    Mindfulness and Meditation

    • Focus on the Now: Anxiety often pulls us into future worries. Mindfulness can help center you in the present.
    • Body Scan: Consciously relax your muscles, releasing any tension.

    Positive Self-Talk

    • Challenge anxious thoughts and replace them with calming affirmations like “I can handle this” or “This feeling will pass.”

    Physical Activity

    • A short walk, yoga, or stretching releases endorphins, naturally easing anxiety.

    Progressive Muscle Relaxation

    • Tense and release muscle groups, starting from your toes up to your head, to calm both body and mind.

    Cold Water Splash

    • Splash your face with cold water or use an ice pack on your neck to stimulate your vagus nerve, which helps slow your heart rate.

    Limit Caffeine and Sugar

    • These can worsen anxiety. Switch to decaf or water when you’re feeling on edge.

    Visualization

    • Picture a peaceful place in your mind. Close your eyes and immerse yourself in the calming details.

    Talk to Someone

    • Reach out to a friend, partner, or therapist. Sometimes simply sharing what you’re feeling makes all the difference.

    By implementing these strategies, we can manage anxiety before it escalates into something harmful. You deserve peace—and taking these steps can help you find it.

  • U.S. Overdose Deaths Hit Historic Low: A Turning Point in the Opioid Crisis

    U.S. Overdose Deaths Hit Historic Low: A Turning Point in the Opioid Crisis

    A recent NPR exclusive reveals a significant and unexpected decline in U.S. overdose deaths, marking the first drop in decades. Data from the Centers for Disease Control and Prevention (CDC) shows a nationwide reduction of roughly 10.6% in overdose deaths. Some states with rapid data collection have seen declines as high as 20-30%, suggesting the possibility of saving up to 20,000 lives annually.

    This turnaround follows years of increasing fatalities, largely driven by fentanyl and other synthetic opioids. Experts credit the broader availability of life-saving treatments, such as naloxone, and improvements in support systems for people at risk of overdosing. While the overall number of overdose deaths remains high, many in the public health community are cautiously optimistic, believing the worst of the crisis might be over for now